Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALNY 
Alnylam Pharmaceuticals Inc (ALNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: ALNY (3-star) is a REGULAR-BUY. BUY since 124 days. Simulated Profits (64.90%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
33 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $477.32
1 Year Target Price $477.32
| 12 | Strong Buy |
| 12 | Buy |
| 7 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 48.77% | Avg. Invested days 33 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 59.78B USD | Price to earnings Ratio 1425.12 | 1Y Target Price 477.32 |
Price to earnings Ratio 1425.12 | 1Y Target Price 477.32 | ||
Volume (30-day avg) 33 | Beta 0.35 | 52 Weeks Range 205.87 - 495.55 | Updated Date 11/1/2025 |
52 Weeks Range 205.87 - 495.55 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When Before Market | Estimate 1.44 | Actual 2.9 |
Profitability
Profit Margin 1.36% | Operating Margin (TTM) 29.46% |
Management Effectiveness
Return on Assets (TTM) 3.65% | Return on Equity (TTM) 32.72% |
Valuation
Trailing PE 1425.12 | Forward PE 46.51 | Enterprise Value 58865594124 | Price to Sales(TTM) 18.62 |
Enterprise Value 58865594124 | Price to Sales(TTM) 18.62 | ||
Enterprise Value to Revenue 23.91 | Enterprise Value to EBITDA 204.85 | Shares Outstanding 131079015 | Shares Floating 126818526 |
Shares Outstanding 131079015 | Shares Floating 126818526 | ||
Percent Insiders 3.82 | Percent Institutions 99.77 |
Upturn AI SWOT
Alnylam Pharmaceuticals Inc
Company Overview
History and Background
Alnylam Pharmaceuticals, founded in 2002, is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics. It pioneered the development of RNAi-based medicines, targeting specific genes to treat genetic diseases.
Core Business Areas
- RNAi Therapeutics Development: Alnylam develops and commercializes RNAi therapeutics targeting genetic diseases with unmet medical needs.
- Research and Development: The company invests heavily in research and development to expand its pipeline of RNAi-based therapies.
- Commercialization: Alnylam commercializes its approved therapies through its own sales force and partnerships.
Leadership and Structure
Alnylam is led by CEO Yvonne Greenstreet. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- ONPATTRO (patisiran): ONPATTRO is an RNAi therapeutic approved for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy. It is a market leader in hATTR amyloidosis treatment with significant revenue. Competitors include Pfizer (VYNDAMAX/VYNDAQEL) and Ionis Pharmaceuticals (TEGSEDI).
- GIVLAARI (givosiran): GIVLAARI is an RNAi therapeutic approved for the treatment of acute hepatic porphyria (AHP). It faces competition from other therapies used to manage AHP symptoms. Competitors include Recordati Rare Diseases (PANHEMTIN).
- OXLUMO (lumasiran): OXLUMO is an RNAi therapeutic approved for the treatment of primary hyperoxaluria type 1 (PH1). Competitors include Dicerna Pharmaceuticals acquired by Novo Nordisk and other supportive therapies.
- AMVUTTRA (vutrisiran): AMVUTTRA is another RNAi therapeutic for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy. It's a next-generation subcutaneous therapy, also competing with Pfizer and Ionis Pharmaceuticals.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the rare disease segment, is characterized by high growth potential, substantial R&D investments, and regulatory complexities. RNAi therapeutics are a relatively new and rapidly evolving area.
Positioning
Alnylam is a leader in the RNAi therapeutics space, with a strong portfolio of approved products and a robust pipeline. Its competitive advantage lies in its proprietary RNAi technology platform and deep expertise in developing and commercializing RNAi drugs.
Total Addressable Market (TAM)
The total addressable market for Alnylam's current and pipeline therapies is estimated to be in the billions of dollars, growing with increasing diagnosis rates and market penetration of RNAi drugs. Alnylam is well-positioned to capture a significant share of this TAM.
Upturn SWOT Analysis
Strengths
- Pioneering RNAi technology platform
- Approved and commercialized RNAi therapeutics
- Strong R&D pipeline
- Expertise in rare disease drug development
- Experienced management team
Weaknesses
- High R&D costs
- Reliance on a novel technology
- Competition from established pharmaceutical companies
- Limited number of approved products
- Dependence on patent protection
Opportunities
- Expansion into new therapeutic areas
- Development of next-generation RNAi therapeutics
- Strategic partnerships and collaborations
- Increased awareness and acceptance of RNAi technology
- Growing market for rare disease treatments
Threats
- Regulatory hurdles
- Clinical trial failures
- Generic competition
- Pricing pressures
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- PFE
- IONS
- VRTX
Competitive Landscape
Alnylam's advantages include its focus on RNAi therapeutics and its strong intellectual property position. Disadvantages include the relatively high cost of RNAi drug development and competition from larger, more established pharmaceutical companies.
Major Acquisitions
Sirna Therapeutics
- Year: 2006
- Acquisition Price (USD millions): 25
- Strategic Rationale: Strengthened Alnylam's RNAi technology portfolio and intellectual property.
Growth Trajectory and Initiatives
Historical Growth: Alnylam's historical growth is marked by successful clinical trials, regulatory approvals, and increasing product sales. The company has transformed from a research-focused entity to a commercial pharmaceutical company.
Future Projections: Future growth projections are positive based on analyst estimates and the potential of the company's pipeline. Revenue is expected to increase as Alnylam expands its market share and launches new products.
Recent Initiatives: Recent initiatives include advancing clinical trials for new RNAi therapeutics, expanding commercial operations in key markets, and forging strategic partnerships with other pharmaceutical companies.
Summary
Alnylam Pharmaceuticals is a leader in the RNAi therapeutics field with approved products addressing rare diseases. The company's strengths include its innovative technology platform and growing commercial presence. Challenges include high R&D costs and competition from larger pharmaceutical firms. Alnylam needs to capitalize on its pipeline and strengthen its market position to ensure continued growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market conditions and company performance can change, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alnylam Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2004-05-28 | CEO & Director Dr. Yvonne L. Greenstreet M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2230 | Website https://www.alnylam.com |
Full time employees 2230 | Website https://www.alnylam.com | ||
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.